Multiple Sclerosis Trial, Recruiting (NCT06567197)

Multiple Sclerosis Trial, Recruiting NCT06567197 Sponsor: Amsterdam UMC, location VUmc Condition: Multiple Sclerosis

Printed from Voxsanity (voxsanity.com.au) — NCT06567197 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Multiple Sclerosis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been approved for a specific stem cell transplant treatment (called aHSCT) for relapsing-remitting multiple sclerosis (RRMS) by the relevant authorities in the Netherlands, following Dutch national guidelines

Who may not be able to join:

People who have a known allergy or sensitivity to any of the medications used in the stem cell transplant treatment
People who have other significant health conditions that would make it unsafe to use the medications involved in the stem cell transplant treatment
People who have severe clinical depression
People who are currently struggling with an active addiction to drugs or alcohol
People who have an active infection, including (but not limited to) tuberculosis, cytomegalovirus, Epstein-Barr virus, herpes simplex, chickenpox, viral hepatitis, toxoplasmosis, HIV, or syphilis
People who currently have cancer, or who have had cancer in the past — with the exception of a specific type of localised skin cancer (basal cell carcinoma) or a very early-stage cervical cell change (carcinoma in situ of the cervix)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: J. Killestein, MSc, PhD, Amsterdam UMC

Phone: +31627228507

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06567197

Sponsor: Amsterdam UMC, location VUmc

Phase: Not Applicable

Status: Recruiting

Condition: Multiple Sclerosis

Trial contact: +31627228507

More information: https://clinicaltrials.gov/study/NCT06567197

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been approved for a specific stem cell transplant treatment (called aHSCT) for relapsing-remitting multiple sclerosis (RRMS) by the relevant authorities in the Netherlands, following Dutch national guidelines

Who may not be able to join:

People who have a known allergy or sensitivity to any of the medications used in the stem cell transplant treatment
People who have other significant health conditions that would make it unsafe to use the medications involved in the stem cell transplant treatment
People who have severe clinical depression
People who are currently struggling with an active addiction to drugs or alcohol
People who have an active infection, including (but not limited to) tuberculosis, cytomegalovirus, Epstein-Barr virus, herpes simplex, chickenpox, viral hepatitis, toxoplasmosis, HIV, or syphilis
People who currently have cancer, or who have had cancer in the past — with the exception of a specific type of localised skin cancer (basal cell carcinoma) or a very early-stage cervical cell change (carcinoma in situ of the cervix)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Amsterdam UMC, location VUmc

Registry

ClinicalTrials.gov

Start date

25 August 2023

Est. completion

1 September 2028

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Treatment efficacy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov